Skip to content

Intervention study on procedural pain caused by subcutaneous injection of recombinant human granulocyte colony-stimulating factor in patients with hematological malignancies

Intervention study on procedural pain caused by subcutaneous injection of recombinant human granulocyte colony-stimulating factor in patients with hematological malignancies

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061507
Enrollment
Unknown
Registered
2022-06-27
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural pain caused by subcutaneous injection of recombinant human granulocyte colony-stimulating factor in patients with hematological malignancies

Interventions

N2O/O2 mixture group:N2O/O2
O2 group:O2

Sponsors

Shenzhen University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 and above; 2. rhG-CSF has no pain before H; 3. The patient was conscious and able to correctly understand and use Numeric Rating Scale (NRS) to express the degree of pain; 4. The patient was diagnosed as HM and rhG-CSF with 4 points of H operating pain (NRS); 5. The condition permits monitoring of vital signs; 6. Participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The patient suffers from intestinal obstruction; Air embolization; Pneumothorax; Lung cancer; Pneumoencephalography; Epilepsy; Upper respiratory tract infection (cold, bronchitis); Airway obstructive diseases (allergies, nasal polyps, sinusitis); Chronic obstructive respiratory diseases (emphysema, chronic bronchitis, asthma); Diseases of the ear, nose and throat (sinusitis, middle ear disease, tympanic membrane transplantation); Intending to become pregnant or in the stage of pregnancy; Vitamin B12 or folic acid deficiency, immunosuppression; Coma, pneumoencephalography, or diving in the last 1 week; Diving sickness; Severe drug dependence and psychiatric disorders such as schizophrenia and claustrophobic delusions; 2. Patients in critical condition; 3. History of nitrous oxide allergy.

Design outcomes

Primary

MeasureTime frame
Pain;

Secondary

MeasureTime frame
Level of anxiety;Fear of pain;Satisfaction with pain relief;Acceptance of the analgesic method;BP, P, SpO2;Adverse effects;

Countries

China

Contacts

Public ContactJun-Jun Zhang

Shenzhen University General Hospital

2281912395@qq.com+86 0755-21839999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026